Concepedia

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

Viktoria Blumenberg, Galina Busch, S. Baumann, Regina Jitschin, Gloria Iacoboni, Laura Gallur, Josu Iraola‐Truchuelo, Eva Hoster, Michael Winkelmann, Konstantin Hellwig,

Blood Advances · 2023 · 33 citations · 22 references

DOI Full text

Open access

Concepts

Life SciencesHematologyOncologyCancer ImmunologyCellular ImmunologyImmunotherapyCytotoxic T Lymphocyte ResponsesEffector T Cell FunctionFlow CytometryT Cell ActivationT Cell BiologyT Cell DifferentiationCd19-directed Bispecific AntibodiesFlow Cytometric Cell AnalysisFlow Cytometry ImmunophenotypingHematologic Malignancy Car T-cell TherapyT-cell Immune Monitoring

Abstract

Blumenberg, Viktoria; Busch, Galina; Baumann, Stephan; Jitschin, Regina; Iacoboni, Gloria; Gallur, Laura; Iraola-Truchuelo, Josu; Hoster, Eva; Winkelmann, Michael; Hellwig, Konstantin; Schmidt, Christian; Frölich, Lisa; Tast, Benjamin; Hildebrand, Friederike; Rejeski, Kai; Dekorsy, Franziska; Schmidkonz, Christian; Bäuerle, Tobias; Kunz, Wolfgang G.; Mougiakakos, Dimitrios; Müller, Fabian; von Bergwelt-Baildon, Michael; Barba, Pere; Bücklein, Veit; Mackensen, Andreas; Völkl, Simon; Subklewe, Marion

References

22

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text

Medicine, Hematology, Oncology +16

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning et al. · The Lancet · 2020 · 2.3K citations

Medicine, Oncology, Pharmacology +13

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.3K citations

Medicine, Oncology, Pharmacology +12

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil, Michael D. Jain, Lei Feng et al. · Journal of Clinical Oncology · 2020 · 786 citations · Full text

Medicine, Hematology, Oncology +17

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

Caron A. Jacobson, Bradley D. Hunter, Robert Redd et al. · Journal of Clinical Oncology · 2020 · 345 citations · Full text

Medicine, Oncology, Pharmacology +17